Literature DB >> 3791658

Insulin-like growth factor I (IGF-I) in healthy children, adolescents and adults as determined by a radioimmunoassay specific for the synthetic 53-70 peptide region.

A Silbergeld, A Litwin, S Bruchis, I Varsano, Z Laron.   

Abstract

A radioimmunoassay (RIA) specific for the synthetic 53-70 peptide region of human insulin-like growth factor I (IGF-I) was used to determine IGF-I in the serum of 191 healthy newborns, children and adolescents and in 26 adults. The results compare favourably with reported values obtained using RIA systems for the native IGF-I molecule. Intra- and inter-assay CV were 3.3 and 7.2% respectively. In childhood, mean +/- SD IGF-I levels rise from 6.0 +/- 3.5 nmol/l in newborns to 16.5 +/- 4.0 nmol/l at 8-11 years in both sexes. At the onset of puberty, IGF-I levels in females (24.9 +/- 6.6 nmol/l) are significantly (P greater than 0.005) higher than in males (17.2 +/- 4.2 nmol/l). With further pubertal development IGF-I levels continue to rise, reaching peak values at pubertal stage P4 (40.6 +/- 4.5 nmol/l in males, 42.8 +/- 5.1 nmol/l in females) and decline thereafter to lower values during adulthood: 16.5 +/- 5.8 nmol/l (males) and 24.2 +/- 7.0 nmol/l (females) (P greater than 0.001). In pubertal males, IGF-I correlates significantly with height (r = 0.66, P less than 0.001), bone age (r = 0.69, P less than 0.001) and growth velocity (r = 0.64, P = 0.025) as well as with testosterone levels (r = 0.69, P less than 0.001). In pubertal females a significant correlation is found between IGF-I and height (r = 0.55, P less than 0.020). The ready availability of a simple, precise and reproducible IGF-I RIA, should contribute much to evaluating the importance of IGF-I measurements in normal growth and in the diagnosis and therapy of various growth disorders.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3791658     DOI: 10.1111/j.1365-2265.1986.tb03596.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

Review 1.  Clinical use of somatomedin-1: yes or no?

Authors:  Z Laron
Journal:  Paediatr Drugs       Date:  1999 Jul-Sep       Impact factor: 3.022

2.  General overgrowth in the fragile X syndrome: variability in the phenotypic expression of the FMR1 gene mutation.

Authors:  B B de Vries; H Robinson; I Stolte-Dijkstra; C V Tjon Pian Gi; P F Dijkstra; J van Doorn; D J Halley; B A Oostra; G Turner; M F Niermeijer
Journal:  J Med Genet       Date:  1995-10       Impact factor: 6.318

Review 3.  The two faces of growth: benefits and risks to bone integrity.

Authors:  A M Parfitt
Journal:  Osteoporos Int       Date:  1994-11       Impact factor: 4.507

4.  Excessive growth in a child with craniopharyngioma and growth hormone deficiency.

Authors:  J M Wit; A Schuitema-Dijkstra; S van Buul-Offers; F Opmeer; J L Van den Brande
Journal:  Eur J Pediatr       Date:  1988-08       Impact factor: 3.183

5.  Testosterone esters advance skeletal maturation more than growth in short boys with chronic renal failure and delayed puberty.

Authors:  M W Van Steenbergen; J M Wit; R A Donckerwolcke
Journal:  Eur J Pediatr       Date:  1991-07       Impact factor: 3.183

6.  Blood lead levels and serum insulin-like growth factor 1 concentrations in peripubertal boys.

Authors:  Abby F Fleisch; Jane S Burns; Paige L Williams; Mary M Lee; Oleg Sergeyev; Susan A Korrick; Russ Hauser
Journal:  Environ Health Perspect       Date:  2013-04-26       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.